News

CNA2h
CNA938 Rewind - A Letter to Myself: How Sabrina Anis' ALS diagnosis helped her experience love more deeply
Sabrina Anis was in university when she was diagnosed with Amyotrophic Lateral Sclerosis (ALS), an incurable condition that ...
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) ...
ALS drug testing in patient-derived cells provides personalized window into nervous system
Unlike other pathologies, amyotrophic lateral sclerosis (ALS) cannot be reproduced accurately in animal models, complicating ...
ALS News Today18h
Clene eyeing regulatory submission for CNM-Au8 in ALS by year’s end
Clene will soon meet with the Food and Drug Administration to discuss analyses that could support an application for ...
Sugar-coated nanotherapy dramatically improves neuron survival in Alzheimer's model
Scientists at Northwestern University have developed a new approach that directly combats the progression of ...
Business Wire4d
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
About Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease in the US and Charcot’s disease in Europe, is a progressive neurodegenerative disorder ...
Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds
The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...
Queen Mary University of London2d
New combination treatment could extend the lifetime of people with amyotrophic lateral sclerosis (ALS)
The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...
TMCnet23h
Positive EMA Opinion on Pediatric Investigation Plan for PolTREG's Treg Therapy in Type 1 Diabetes
The PDCO’s positive opinion is based on PolTREG’s original preTreg clinical trial protocol initiated in October 2024, which enrolled children aged 6–16 years in Stage 1 type 1 diabetes. In its ...